Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beta cell reactivity defines disease-relevant pancreatic CD8 T cells in type 1 diabetes.

bioRxiv : the preprint server for biology·2026
Same author

Helitrons are enriched in lichenized fungi with long generation lengths and small distribution sizes.

G3 (Bethesda, Md.)·2026
Same author

Hemoglobin-albumin-lymphocyte-platelet score associated with diabetic foot severity, unlike modified systemic immune-inflammatory index and modified systemic inflammatory response index.

Frontiers in endocrinology·2026
Same author

Thymic alveolar type 2 epithelial mimetic cells revealed by RUNX1 deficiency.

Nature immunology·2026
Same author

Runx3 instructs Aire<sup>+</sup> mTEC development, TSA gene expression, and central tolerance.

Journal of autoimmunity·2026
Same author

Generation of Functional Patient-Specific Thymus Organoids From Human Pluripotent Stem Cells (hPSCs) Using Air-Liquid Interface Culture.

Bio-protocol·2026

Related Experiment Video

Updated: Feb 25, 2026

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating
05:35

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Published on: June 23, 2018

7.8K

Nanoporous Immunoprotective Device for Stem-Cell-Derived β-Cell Replacement Therapy.

Ryan Chang1, Gaetano Faleo, Holger A Russ

  • 1UCSF-UC Berkeley Joint PhD Program in Bioengineering , San Francisco, California 94143, United States.

ACS Nano
|August 2, 2017
PubMed
Summary

Encapsulating human embryonic stem-cell-differentiated beta cell clusters (hES-βC) in a nanoporous device shows promise for diabetes treatment. This technology provides immune protection and nutrient exchange, enabling long-term cell survival and function in vivo.

Keywords:
cell encapsulation devicecell therapydiabetesimmunoengineeringnanotechnology

More Related Videos

Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System
10:12

Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System

Published on: December 16, 2021

3.3K
Author Spotlight: Advancements and Challenges in &#946;-Cells Differentiation from Pluripotent Stem Cells
06:33

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells

Published on: February 2, 2024

2.7K

Related Experiment Videos

Last Updated: Feb 25, 2026

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating
05:35

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Published on: June 23, 2018

7.8K
Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System
10:12

Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System

Published on: December 16, 2021

3.3K
Author Spotlight: Advancements and Challenges in &#946;-Cells Differentiation from Pluripotent Stem Cells
06:33

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells

Published on: February 2, 2024

2.7K

Area of Science:

  • Biomedical Engineering
  • Regenerative Medicine
  • Immunology

Background:

  • Diabetes treatment often requires lifelong immune suppression for cell therapies.
  • Human embryonic stem-cell-differentiated beta cell clusters (hES-βC) offer a potential cell source for diabetes therapy.
  • Effective immune protection is crucial for the success of transplanted cells.

Purpose of the Study:

  • To develop and evaluate a nanoporous immunoprotective polymer thin film device for encapsulating hES-βC.
  • To assess the biocompatibility and efficacy of the encapsulation device in vivo.
  • To determine if the device can prevent immune rejection and allow long-term cell function.

Main Methods:

  • Fabrication of a nanoporous polymer thin film encapsulation device.
  • In vitro assessment of oxygen and nutrient exchange and immune molecule exclusion.
  • In vivo biocompatibility studies, including neovascularization and foreign body response assessment.
  • Evaluation of teratoma containment and long-term engraftment, viability, and function of encapsulated hES-βC in animal models.

Main Results:

  • The device successfully excluded immune molecules while allowing essential nutrient and oxygen exchange.
  • Biocompatibility studies showed the device promoted neovascularization with a limited foreign body response.
  • The device prevented teratoma escape and demonstrated successful immuno-isolation of encapsulated cells.
  • Long-term (6-month) animal studies confirmed engraftment, viability, and function of encapsulated hES-βC.

Conclusions:

  • Nanoporous polymer thin film encapsulation is a viable strategy for protecting transplanted cells.
  • This technology enables immune-isolated cell therapy for diabetes without systemic immunosuppression.
  • The developed device supports long-term survival and function of hES-βC, paving the way for potential clinical applications.